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Background: In 2005, the Italian Society for Artificial Nutrition and Metabolism carried out a national survey on the
prevalence of home artificial nutrition (HAN), enteral (HEN) and parenteral (HPN). A second survey was carried out
in 2012 to investigate the development of HAN in Italy.
Methods: The Local Health Care Units (LHCUs) were required to record the ongoing cases of HAN using a structured
questionnaire. The point prevalence (n./million inhabitants) was analysed according to patient age and disease categories.
Data were compared with those obtained in 2005.
Results: Data were obtained from 65% of the LHCUs, representing 73% of the Italian population. The prevalence of HAN
was 325.5 (90.3% adults, 84.6% HEN). As in 2005, a wide range of prevalence was observed among the administrative
regions. The most frequent disease category for HPN was oncological in adults and intestinal failure in children; for HEN, it
was neurological in both age groups. A positive correlation was observed between the regional prevalence of HAN and
the regional population aging index (p = 0.018). The prevalence of HAN in 2012 was 66% higher than that in 2005. In the
individual regions, a negative association was observed between the 2012% prevalence increase of HAN (2012:2005 ratio)
and the HAN prevalence in 2005 (p = 0.020).
Conclusions: A two-thirds increase in HAN prevalence was observed over seven years, probably due to improved HAN
organisation and management in those regions which showed a low prevalence in 2005. Population aging seemed to be
one of the main factors necessitating HAN.
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In 2005, the Italian Society for Artificial Nutrition and
Metabolism (SINPE) carried out the first national survey
regarding the prevalence of home artificial nutrition
(HAN), both enteral (HEN) and parenteral (HPN) [1].
The national point prevalence of HAN was 195.6 cases
per million inhabitants. Of the total cases of HAN,
approximately 84% were HEN (16% HPN) and approxi-
mately 94% were adults (6% children). The primary
disease category for HPN was oncological in adults
(60%) and intestinal failure in children (58%). For HEN,
the primary disease category was neurological in both
age groups (73% in adults and 50% in children).Correspondence: loris.pironi@unibo.it
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(http://creativecommons.org/publicdomain/zeThe Italian National Health Care System (NHCS) is
regulated by legislation which defines the general rules for
providing health care. The Italian territory is divided into
20 administrative regions which are responsible for
providing health care to their residents. In the individual
regions, the territory is divided into local health care units
(LHCUs) which are the operative arms of the Regional
Health Care System. The LHCUs are empowered by
national legislation to give HAN to patients in need.
However, in the majority of the regions, a regional regula-
tion for HAN has been issued in order to facilitate the im-
plementation of HAN activity at the LHCU level. In 2005,
a broad range of prevalence was found among the admin-
istrative regions for both total HAN and disease category
distribution. The prevalence was related to the percentage
of elderly people in the individual regions. Furthermore, a
trend was observed toward a higher prevalence of HAN in
those regions with a HAN regulation, but it was alsole is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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related to LHCU organisation since the latter has the task
of implementing the regulation.
Home artificial nutrition activity plays a key role in
shortening the hospital length of stay of clinically stable
hospitalised patients who are ready to be discharged but
who are in need of artificial nutrition. To investigate the
development of HAN activity throughout the country is
valuable in the organisation and funding of health care
activities. For this purpose, in 2012, SINPE carried out a
second survey regarding the prevalence of HAN in Italy.
The data were compared with those obtained in 2005 [1].
Methods
Data collection
This was a cross sectional survey aimed at investigating
the point prevalence of HAN, carried out with the same
methodology used in the 2005 survey [1]. The data were
collected in April 2012 by the SINPE Coordinators of
the Italian administrative regions.
Using a structured questionnaire (Fig. 1), the LHCUs
were asked to record the ongoing number of cases of HPN,
HEN and mixed HAN (HPN+HEN). Home parenteralFig. 1 Structured questionnaire used for the survey regarding the point prnutrition was defined as nutrition via a central or peripheral
vein using all-in-one nutritional bags. Home enteral nutri-
tion was defined as the administration of an enteral feeding
formula by a nasogastric (or jejunal) tube, a percutaneous
endoscopic gastrostomy or a jejunostomy. The patient age
category was classified as adult (>18 years) or paediatric.
The primary disease was classified as oncological, neuro-
logical, benign (non malignant) chronic intestinal failure
(CIF) or other diseases. However, the recently published
European Society for Clinical Nutrition and Metabolism
(ESPEN) recommendations regarding the definition and
classification of intestinal failure has defined “intestinal
failure” as a condition requiring intravenous feeding and
“intestinal insufficiency” as a condition requiring enteral or
oral supplementation [2]. In order to adapt the results of
the Italian survey to the ESPEN definitions, in the present
paper, the disease category “benign CIF” has been replaced
with the term “gastrointestinal disease” (GI disease).
Ethical rules
The study exclusively records and elaborates data concern-
ing the HAN activity of the Italian LHCUs. The research
was based on the count of the number of patients receivingevalence of home artificial nutrition in Italy in 2005 and 2012
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or sensitive data that could allow individual patient recogni-
tion and tracking was collected. Nevertheless, the study
protocol was submitted to the Ethical Committee (EC) of
the S. Orsola-Malpighi University Hospital of Bologna,
Italy. The EC replied that considering the administrative
type of the investigation without treatment of personal data
of patients, neither the prior acquisition of the opinion of
the EC nor the informed consent of patients were necessary.Statistical analysis
The completed questionnaires were collected and ana-
lysed by the study coordinator (LP).
The representativeness of the survey was calculated as
the percentage of the regional and the national population,
and of the territorial extension represented by the LHCUs
which contributed to the study (http://www.salute.gov.it,
accessed September 14th 2012).
Point prevalence was defined as the number of HAN
cases actually recorded per million inhabitants. When
required for statistical analyses, mixed HAN cases (HPN
+HEN) were considered as HPN.
The regional population aging index, represented by the
ratio “% population ≥ 65 years/% population < 15 years” was
that calculated by the Italian National Institute of Statistics
(http://noi-italia.istat.it/, accessed September 14th 2012).
Comparison between the groups was carried out using
the Mann–Whitney U test, and the associations between
the variables were analysed using the Spearman rank
correlation coefficient. The Statgraphics 5 Plus statistical
package (Manugistic, Inc., Rockeville, Maryland, USA) was
used for the analyses.Results
Representativeness of the survey
Eighteen of the 20 Italian administrative regions partici-
pated in the survey. Ninety-five of the 146 national LHCUs
(65.5%) contributed, representing a territorial extent of
204,160 km2 (67.8% of total) and 44.36 million inhabitants
(73.2% of total). On a regional basis, the representativeness
of the population of the LHCUs which contributed to the
survey ranged from 31 to 100% of the total regional popula-
tion (Fig. 2).National point prevalence of HAN
The number of recorded cases of HAN was 14,441
(90.3% adult and 9.7% paediatric patients). The preva-
lence of HAN was 325.5/per million inhabitants (84.6%
HEN, 14.6% HPN and 0.8% HPN +HEN).
The prevalence of HPN (including the HPN +HEN
cases) was 50.2 per million inhabitants and that of HEN
was 275.3 per million inhabitants (Table 1 and Fig. 3).Of the disease categories, oncological diseases accounted
for 19.4% of the total HAN, neurological diseases for 64.8%,
GI disease for 6.5% and other diseases for 9.3%. In adult pa-
tients, HPN and HEN were 15.7% and 84.3% of total HAN,
respectively; the main disease category was oncological
(60.3%) for HPN and neurological (75.6%) for HEN. In
paediatric patients, HPN and HEN were 13.0% and 87.0%
of the total HAN, respectively; the main disease category
distribution was GI disease (49.7%) for HPN and neuro-
logical (63.4%) for HEN (Table 2 and Fig. 4).
Regional point prevalence of HAN
A wide range of HAN prevalence (from 100.9 per million
inhabitants in Calabria to 828.4 per million inhabitants in
Umbria), as well as of the use of HAN in the age and dis-
ease categories were reported among the regions (Table 3).
A positive association was observed between the
regional aging index and the regional prevalence of HAN
(r = 0.572; p = 0.018) (Fig. 5). When the association was
analysed for each disease category, only the association
with HAN for neurological diseases remained statistically
significant (neurological: r = 0.624, p = 0.010; oncological:
r = 0.310, p = 0.200; GI disease: r = −0.019, p = 0.935; other
diseases: r = −0.005, p = 0.982).
Comparison with the 2005 survey
The comparison between HAN use in 2005 and in 2012
was calculated as a 2012 to 2005 ratio of the observed
prevalence (Tables 3 and 4).
On a national basis, the HAN prevalence showed a
66% increase. The increase in HEN prevalence was
slightly greater than that of HPN, 68% and 58%, respect-
ively. The increase in paediatric patients was 2-fold
greater than the increase in adult patients. Concerning
the disease categories, the greatest increase was observed
in the GI disease group which, however, remained the
smallest group by far (Table 4).
Comparison on a regional basis was possible for only 15
regions (Table 3). A wide range of increase in HAN preva-
lence was observed. A statistically significant negative asso-
ciation was observed between the regional prevalence of
HAN observed in 2005 and the percentage increase of
HAN regional prevalence observed in 2012 (r = −0.617, p =
0.020) (Fig. 6). This association was also present in the
single disease categories (neurological: r = −0.425, p = 0.111;
oncological: r = −0.675, p = 0.011; GI disease: r = −0.550,
p = 0.029; other diseases: r = −0.293, p = 0.272).
Six regions issued or modified an existing regulation
after the 2005 survey (Table 3). In this group of regions,
the median increase in HAN prevalence between 2005
and 2012 was 121% which, even though not statistically
significant, was 2-fold that of the median increase (64%)
observed in the group of the 9 regions which did not




















Fig. 2 Italian administrative regions. Red: regions where the survey covered 100% of the population; light blue: regions where the survey covered 50 to
85% of the population; yellow: regions where the survey covered 31 to 46% of the population; white: regions which did not contribute to the survey
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This second epidemiological survey regarding HAN in
Italy showed a 66% increase in the point prevalence of
HAN over seven years, but no variations occurred con-
cerning the characteristics of the HAN usage investi-
gated by the survey. In 2012, the heterogeneity of HAN
prevalence among the administrative regions, the HENTable 1 National point prevalence (n./million of inhabitants) of
home artificial nutrition (HAN), both parenteral (HPN) and enteral
(HEN), in Italy in 2012. Total cases and cases by age category
HAN HPNa HEN
Total cases (n. 14,441) 325.5 50.2 275.3
Adult (n. 13,046) 294.0 46.1 247.9
Pediatric (n. 1,395) 31.4 4.1 27.3
apatients receiving both HPN and HEN were included in the HPN group; the HPN+
HEN cases were 3.7% of total HPN in adults and 21.9% of total HPN in children
Population sample: 44.36 million inhabitants (73.2% of total Italian population)to HPN use ratio as well as the HAN distribution be-
tween the patient age categories and among the disease
categories were similar to those observed in 2005 [1].
The representativeness of the survey was good because
it covered more than two-thirds of both the national
population and territory.Fig. 3 Prevalence of home artificial nutrition (HAN) in Italy in 2012:
percentages of age categories of patients on HAN and percentages
of enteral (HEN), parenteral (HPN) and mixed (HPN + HEN) types
Table 2 Point prevalence (n./million of inhabitants) of home artificial nutrition (HAN), both parenteral (HPN) and enteral (HEN) by
disease category, in Italy in 2012
Total cases Adult Paediatric
HAN HPNa HEN HAN HPNa HEN HAN HPNa HEN
Oncological 63.5 28.8 34.7 61.6 28.2 33.4 1.9 0.6 1.3
Neurological 212.2 7.1 205.1 193.3 5.7 187.5 18.9 1.3 17.6
GI disease 21.3 11.7 9.6 15.8 9.4 6.4 5.5 2.3 3.1
Other 30.4 3.8 26.5 24.2 3.4 20.8 6.1 0.4 5.7
apatients receiving both HPN and HEN were included in the HPN group
Population sample: 44.36 million inhabitants (73.2% of total Italian population)
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been due to several causes. The main factor could have
been the increased awareness of the role of HAN among
health care professionals as well as the improvement of
HAN organisation and management at the LHCU level.
This hypothesis was supported by the observed inverse
association between the regional prevalence of HAN
reported in 2005 and its percentage of increase in 2012,
indicating a greater increase in those regions where HAN
practice was less developed in 2005. The greater percent-
age increase of HAN prevalence observed in those regions
which have issued or modified an existing HAN regulation
since 2005 may also have contributed. Indeed, as observed
in 2005 [1], a regional regulation could have fostered
HAN for patients in need since it defines the indications,
the organisation and the management of HAN at the
LHCU level. The increase in the Italian population agingFig. 4 Prevalence of on home artificial nutrition (HAN) in Italy in 2012:
percentages of disease categories within the enteral (HEN), parenteral
(HPN and HPN+ HEN) types in either adult or paediatric patientsindex, which was 138.1 in 2005, 148.6 in 2012 and 157.7
in 2015 (noi-italia-istat.it) may also have played a role.
The incidence of stroke as well as that of chronic neuro-
logical diseases, such as dementia and Parkinson’s disease
which may permanently impair the patient’s ability of oral
feeding, increase with aging. As we have observed, a posi-
tive relationship between the prevalence of HAN for
neurological disease and the regional population aging
index, a further progressive increase in the need for HAN
in neurological disease could be expected in the near fu-
ture. Another factor could be the NHCS policy aimed at
reducing the hospitalisation rate and the length of stay of
patients with chronic diseases, and at facilitating home
and residential care. Furthermore, increased efficacy of
data collection may have played a role, even though the
representativeness of the sample population in 2012 (74%
of total Italian population) was similar to that of the 2005
investigation (78%).
In comparison with 2005, the increase in HEN preva-
lence was slightly greater than that of HPN, and the in-
crease in paediatric cases (9.7% in 2012 vs. 6.5% in 2005)
was greater than that of adult cases. The HEN to HPN ra-
tio did not substantially change (5.4 in 2012 vs. 5.2 in
2005). The distribution of HAN among the disease cat-
egories did not differ, with neurological disease represent-
ing the greatest percentage of cases (61.7% in 2005 and
64.8% in 2012) and GI disease the least (4.0% in 2005 and
6.5% in 2012). As in 2005, oncological diseases accounted
for 60% of HPN in adults, and neurological diseases repre-
sented more than two-thirds of HEN in both adults and
children. According to the ESPEN definition of intestinal
failure [2], on the basis of patients on HPN for GI disease,
the total prevalence of benign CIF in 2012 was 11.7 (9.4 in
adults and 2.3 in children), representing a 2-fold increase
with respect to 2005 (prevalence 4.4). Unfortunately, there
are very few data to be compared with those which were
observed in this study. In the European countries, the point
prevalence of HPN has been reported to range between 5
and 49 cases per million inhabitants [3], with a percentage
of patients having a malignant disease ranging from 5 to
60% [4]. Therefore, the prevalence of HPN for CIF due to
benign disease has been estimated to range from 5 to 20
Table 3 Point prevalence (n./million of inhabitants) of home artificial nutrition (HAN), both parenteral (HPN) and enteral (HE), in the
individual administrative regions in Italy in 2012. Cases for age and disease categories, and total cases. Comparison with the HAN




Adult Paediatric Total HAN (HPN + HEN) by disease category




Valle d’Aosta 149.7 31.2 226.2 0 0 85.7 155.9 23.4 0 257.3
Piemonte 177.7 50.0 222.1 2.7 38.6 66.4 189.3 24.9 32.7 313.4 1.35b
Lombardia 141.1 28.9 315.5 4.4 30.1 71.9 232.1 34.1 58.3 378.8
Veneto 139.8 47.2 413.2 1.9 36.2 92.4 361.4 11.7 32.9 498.5 1.67
Friuli-Ven-Giulia 186.2 15.8 227.0 2.6 168.9 58.0 319.2 11.1 26.3 414.2 1.60
Liguria 232.0 43.4 242.7 6.0 40.9 76.6 224.8 31.3 0 333.0
Emilia-Romagna 167.2 37.0 321.7 2.7 22.3 53.5 282.1 18.8 24.8 383.7 1.14
Toscana 182.9 79.3 449.3 6.3 40.3 84.1 429.8 15.8 44.8 575.2 2.68b
Umbria 178.8 40.2 770.1 5.2 13.0 75.1 735.0 12.1 5.1 828.4 2.30
Marche 168.7 73.5 689.3 1.2 23.0 106.0 554.5 26.8 100.3 787.6 1.06
Lazio 142.0 28.4 205.8 3.4 32.3 47.8 158.1 29.0 42.2 279.9 1.70
Abruzzo 163.2 8.3 136.0 2.8 1.4 16.6 105.5 3.7 22.2 148.5 0.63
Molise 175.8 28.1 315.8 0 25.0 75.0 293.9 0 0 369.0 2.64
Campania 98.7 52.1 84.0 4.1 21.0 59.3 75.2 16.6 12.6 161.2 2.52b
Basilicata 150.6 78.3 32.3 1.7 11.9 59.5 61.2 3.4 0 124.2 0.80b
Puglia 125.2 69.4 85.5 3.4 5.9 45.4 90.1 17.8 12.2 164.2 1.91b
Calabria 132.0 19.4 58.2 5.0 18.4 42.7 38.7 10.4 8.9 100.9 3.06b
Sicilia 122.2 61.0 145.8 11.1 29.0 69.9 148.3 19.7 8.9 246.8 4.41
Regional aging index: %population ≥ 65 yrs/%population < 15 yrs; apatients receiving both HPN and HEN were included in the HPN group
Abbreviations: Onco oncological; neuro: neurological; GI-dis gastrointestinal disease
badministrative regions which issued or modified their HAN regulation after the 2005 survey
Table 4 Comparison between 2005 and 2012 point prevalence
(n. per million inhabitants) of home artificial nutrition (HAN), both
parenteral (HPN) and enteral (HEN), in Italy, calculated as the 2012
to 2005 ratio
2012: 2005 prevalence ratio
Total cases Oncological Neurological GI disease Other
National
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well with the data observed in Italy in 2012.
A wide range of HAN prevalence and distribution
among the disease categories persisted among the admin-
istrative regions and confirmed the non-homogeneous
HAN activity throughout the national territory. The posi-
tive relationship observed between the prevalence of HAN
for neurological disease and the regional population aging
index agrees with that observed in 2005 between theFig. 5 Association between the regional population aging index ratio
(% population≥ 65 years of age to % population < 15 years of age ratio)
and the regional point prevalence of HAN (n./million of inhabitants)
(r= 0.572, p= 0.018)
HAN 1.66 1.34 1.76 2.67 1.54
HPNa 1.58 1.57 1.88 2.07 1.14
HEN 1.68 1.20 1.74 4.36 1.67
Adult
HAN 1.61 1.32 1.67 2.62 1.60
HPNa 1.55 1.55 1.59 1.98 1.11
HEN 1.62 1.18 1.67 4.99 1.73
Paediatric
HAN 3.29 2.47 3.43 2.81 0.48
HPNa 2.16 4.68 10.14 2.24 0.21
HEN 2.55 2.03 3.27 3.45 0.53
apatients receiving both HPN and HEN were included in the HPN group
Total cases and cases by age and disease categories
Fig. 6 Association between the regional point prevalence of HAN
(n. per million of inhabitants) observed in 2005 and the increase of
HAN prevalence observed in 2012 (calculated as 2012 to 2005 ratio)
(r = −0.617, p = 0.020)
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tion over 75 years of age. As neurological disease
accounted for two-thirds of the HAN cases, the regional
differences for HAN prevalence may in part be justified by
the demographic characteristics of the regional popula-
tions. Another explanation is the difference in HAN regu-
lation and organisation among the administrative regions
which would represent a risk for patients in terms of the
opportunity of receiving HAN when needed as well as re-
ceiving appropriate HAN management. Additional inves-
tigation is required to compare the regulations of HAN
issued by the individual regional health care services
concerning indications, organisation, management and
economical resources. In Europe, the only available pro-
spective survey regarding the use of HAN which could be
compared with the 2005 and 2012 surveys in Italy is a
report by the British Artificial Nutrition Survey (BANS), a
committee of the British Association for Parenteral and
Enteral Nutrition (BAPEN), carried out yearly from 2000
to 2010 [5]. Overall, a significant rise in HAN was ob-
served in both countries at a rate of 20–30% per year, but
differences in the use of both HEN and HPN were
present. The prevalence of HPN was approximately 2.5-
fold greater in Italy, in both adult and paediatric patients
whereas the prevalence of HEN was greater in the UK, ap-
proximately 1.4-fold in adults and 10-fold in children.
Concerning the disease categories, the greatest difference
was the use of HPN in adult patients with oncological dis-
ease. They represented 60% of total HPN in Italy and
10-20% in the UK. On the contrary, the use of HEN in
oncological patients was approximately twice that of the
UK. The Italian attitude towards the use of HPN in the
context of palliative care for cancer patients has been well
recognised since the first European survey on HPN in
1993 [4]. Another reason could be the more frequent use
of a central venous catheter previously positioned for
chemotherapy for HPN instead of activating enteral tube
feeding. This may also justify the lower percentage of
HEN for oncological patients in Italy.The Spanish Society for Parenteral and Enteral Nutri-
tion has also implemented a registry for HAN since
2000. However, as the methodology of data recording
greatly differs from that of the Italian and the UK sur-
veys, a comparison with the epidemiology of HAN in
Spain would not give reliable figures [6, 8]. Overall, the
difficulty in comparing data among various countries in-
dicates the need for developing a standard method of
evaluating the epidemiology of HAN.
Conclusions
In conclusion, this second survey regarding the prevalence
of HAN in Italy showed that over seven years: a) HAN
usage has progressively grown at a rate of 20–30% per
year; b) the use of HAN in the age and disease categories
was substantially stable; c) population aging was con-
firmed to be a major factor in determining the need for
HAN; d) HAN diffusion and usage differed greatly
throughout the country; e) a regional regulation of HAN
activity may have favoured its development but did not re-
duce the differences among the regions and f) comparison
with the UK surveys carried out in the same time frame
would indicate a lower use of HEN and a higher use of
HPN in Italy, the latter probably due to the Italian attitude
towards treatment of patients with active cancer. Strat-
egies to make HAN activity more homogenous through-
out the country and clinical research to evaluate the
appropriateness of the different models of providing HAN
are still required. Studies to compare the HAN regional
regulations and to investigate how the current guidelines
on HAN in the individual pathological categories are ap-
plied at the LHCU level, as well as educational plans to
improve their applications, will be the next steps.
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